Gokul Gopalan

1.1k total citations · 1 hit paper
27 papers, 749 citations indexed

About

Gokul Gopalan is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Gokul Gopalan has authored 27 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Physiology, 22 papers in Pulmonary and Respiratory Medicine and 8 papers in Immunology and Allergy. Recurrent topics in Gokul Gopalan's work include Asthma and respiratory diseases (24 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (15 papers) and Respiratory and Cough-Related Research (8 papers). Gokul Gopalan is often cited by papers focused on Asthma and respiratory diseases (24 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (15 papers) and Respiratory and Cough-Related Research (8 papers). Gokul Gopalan collaborates with scholars based in United States, United Kingdom and Singapore. Gokul Gopalan's co-authors include David Price, Mary Buatti Small, Elizabeth V. Hillyer, Ian Pavord, Marjan Kerkhof, Anne Burden, Eugene R. Bleecker, Anna Rigazio, A WILSON and Valerie L. Ashton and has published in prestigious journals such as PLoS ONE, Journal of Allergy and Clinical Immunology and European Respiratory Journal.

In The Last Decade

Gokul Gopalan

25 papers receiving 730 citations

Hit Papers

Blood eosinophil count an... 2015 2026 2018 2022 2015 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gokul Gopalan United States 13 658 495 193 119 79 27 749
Virginie Paulus Belgium 15 703 1.1× 555 1.1× 131 0.7× 117 1.0× 153 1.9× 40 842
Teet Pullerits Sweden 15 576 0.9× 290 0.6× 423 2.2× 50 0.4× 91 1.2× 38 752
Louis Philippe Boulet Canada 8 451 0.7× 426 0.9× 73 0.4× 73 0.6× 59 0.7× 11 625
V. Backer Denmark 12 547 0.8× 416 0.8× 250 1.3× 89 0.7× 31 0.4× 15 715
Giuseppina Rotiroti United Kingdom 10 498 0.8× 148 0.3× 568 2.9× 92 0.8× 66 0.8× 17 734
Tomoshi Takeda Japan 12 551 0.8× 546 1.1× 112 0.6× 35 0.3× 28 0.4× 31 659
Melanie Makhija United States 13 260 0.4× 166 0.3× 191 1.0× 97 0.8× 88 1.1× 35 541
Johannes Martin Schmid Denmark 13 325 0.5× 128 0.3× 300 1.6× 35 0.3× 67 0.8× 43 504
Steen Nepper-Christensen Denmark 12 332 0.5× 196 0.4× 209 1.1× 16 0.1× 29 0.4× 16 480
Y. Darby United Kingdom 16 399 0.6× 250 0.5× 450 2.3× 343 2.9× 30 0.4× 24 899

Countries citing papers authored by Gokul Gopalan

Since Specialization
Citations

This map shows the geographic impact of Gokul Gopalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gokul Gopalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gokul Gopalan more than expected).

Fields of papers citing papers by Gokul Gopalan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gokul Gopalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gokul Gopalan. The network helps show where Gokul Gopalan may publish in the future.

Co-authorship network of co-authors of Gokul Gopalan

This figure shows the co-authorship network connecting the top 25 collaborators of Gokul Gopalan. A scholar is included among the top collaborators of Gokul Gopalan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gokul Gopalan. Gokul Gopalan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahler, Donald A., et al.. (2022). High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 9(3). 427–438. 11 indexed citations
2.
Casciano, Julian, Jill Davis, Kathleen M. Fox, et al.. (2020). Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma. Annals of Allergy Asthma & Immunology. 125(2). 182–189. 4 indexed citations
3.
Edwards, Chelsea L., Alan Kaplan, Barbara P. Yawn, et al.. (2020). Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 8(1). 135–151.
4.
Kerkhof, Marjan, Trung N. Tran, Maarten van den Berge, et al.. (2018). Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS ONE. 13(7). e0201143–e0201143. 30 indexed citations
7.
Kerkhof, Marjan, Trung N. Tran, Maarten van den Berge, et al.. (2017). Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids. Ghent University Academic Bibliography (Ghent University). PA3994–PA3994. 2 indexed citations
9.
Casciano, Julian, Jerry A. Krishnan, Mary Buatti Small, et al.. (2016). Value of peripheral blood eosinophil markers to predict severity of asthma. BMC Pulmonary Medicine. 16(1). 109–109. 25 indexed citations
10.
Virchow, J. Christian, Roberto Rodríguez-Roisin, Alberto Papi, Tushar Shah, & Gokul Gopalan. (2016). A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma. BMC Pulmonary Medicine. 16(1). 42–42. 14 indexed citations
11.
Casciano, Julian, Jerry A. Krishnan, Mary Buatti Small, et al.. (2016). Burden of asthma with elevated blood eosinophil levels. BMC Pulmonary Medicine. 16(1). 100–100. 25 indexed citations
12.
Chrystyn, Henry, et al.. (2015). Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. International Journal of Pharmaceutics. 491(1-2). 268–276. 43 indexed citations
13.
Price, David, Anna Rigazio, Jonathan D. Campbell, et al.. (2015). Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. The Lancet Respiratory Medicine. 3(11). 849–858. 413 indexed citations breakdown →
14.
Price, David, Dirkje Postma, Nicolás Roche, et al.. (2014). Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. International Journal of COPD. 9. 1163–1163. 25 indexed citations
16.
Bernstein, David I., Ariel Teper, Gokul Gopalan, & Davis Gates. (2012). Effects of intranasal mometasone furoate on itchy ear and palate in patients with seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 108(5). 359–362. 6 indexed citations
17.
Meltzer, Eli O., et al.. (2010). Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. Annals of Allergy Asthma & Immunology. 105(1). 65–74. 33 indexed citations
18.
Bousquet, Philippe‐Jean, Claus Bachert, Giorgio Walter Canonica, et al.. (2010). Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA<sup>2</sup>LEN Study. International Archives of Allergy and Immunology. 153(4). 395–402. 36 indexed citations
19.
Price, David, Linda Kemp, Erika Sims, et al.. (2010). Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Primary Care Respiratory Journal. 19(3). 266–273. 14 indexed citations
20.
Kaiser, Harold B., et al.. (2008). Loratadine provides early symptom control in seasonal allergic rhinitis. Allergy and Asthma Proceedings. 29(6). 654–658. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026